Company Profile For H. Lundbeck A/S

H. Lundbeck A/S (Lundbeck) is a Denmark-based company active within the specialty pharmaceuticals industry. The Company is engaged in the research, development, manufacturing and marketing of pharmaceuticals for the treatment of diseases of the central nervous system (CNS). H. Lundbeck A/S operates through global subsidiaries. Its production units are located in Denmark, Italy and Mexico, and research facilities in Denmark and the United States. The Company’s main areas of focus comprise Alzheimer’s disease, depression and mood disorders, alcohol dependence, Parkinson’s disease, primary insomnia, schizophrenia and psychotic disorders, as well as acute ischemic stroke. Its main products include Azilect, for the treatment of Parkinson’s disease; Cipralex/Lexapro, for the treatment of depression and anxiety; Circadin, for the treatment of primary insomnia; Ebixa, for the treatment of moderate to severe Alzheimer’s disease, and Serdolect for the treatment of schizophrenia.

BRIEF: For the nine months ended 30 September 2009, H. Lundbeck A/S' total turnover increased 15% to DKR9.92B. Net profit for the period increased 15% to DKR1.77B. Total turnover reflects increased sales in the European and International markets segments. Net profit for the period benefited from a decrease in research and development costs and an increase in operating margin, as well as a decrease in loss from result in associated companies.